NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT03691064 2025-12-23
SALUS
Advanced Accelerator Applications
Active not recruiting
NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
NCT04727723 2025-10-03
REAL-LU
Advanced Accelerator Applications
Active not recruiting
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT06398444 2025-09-05
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Sinotau Pharmaceutical Group
Phase 2/3 Active not recruiting
NCT04946305 2024-08-09
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
Novartis
Completed
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT02705313 2018-04-09
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications
Approved for marketing